Sarepta Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
AQR Capital Management, LLC and AQR Capital Management Holdings, LLC have disclosed beneficial ownership of over 5% of Sarepta Therapeutics, Inc. common stock, acquiring 5,329,691 shares.
NASDAQ
State Street Corporation and its affiliate SSGA Funds Management, Inc. have filed a Schedule 13G, reporting beneficial ownership of Sarepta Therapeutics Inc. common stock.
NASDAQ
Vanguard Portfolio Management has reported a significant beneficial ownership stake of 8.05% in Sarepta Therapeutics Inc., as of June 30, 2026.
NASDAQ
Vanguard Capital Management has reported a beneficial ownership of 5.11% in Sarepta Therapeutics Inc. common stock as of March 31, 2026.
NASDAQ
Vanguard Portfolio Management has reported beneficial ownership of 6.43% of Sarepta Therapeutics' common stock as of March 31, 2026.
NASDAQ
The Vanguard Group has amended its Schedule 13G filing for Sarepta Therapeutics, reporting 0% beneficial ownership due to an internal reporting realignment.
NASDAQ
AQR Capital Management, LLC and its parent entity have reported a beneficial ownership of 7.73% in Sarepta Therapeutics, Inc., totaling 8,104,869 shares.
NASDAQ
BlackRock, Inc. has reported a 12.6% beneficial ownership stake in Sarepta Therapeutics Inc., holding 13,232,652 shares of common stock as of December 31, 2025.
NASDAQ
D. E. Shaw & Co., L.P. and David E. Shaw have reported a 1.9% beneficial ownership stake in Sarepta Therapeutics, Inc., totaling 2,007,025 shares.
NASDAQ
State Street Corporation has reported a 5.4% beneficial ownership stake in Sarepta Therapeutics Inc., holding over 5.3 million common shares.
NASDAQ
The Vanguard Group has reported an increased beneficial ownership of 10.89% in Sarepta Therapeutics Inc. common stock.
NASDAQ
SCHEDULE 13G/A: Capital International Investors Discloses 0.5% Sarepta Stake
Capital International Investors has filed an amended Schedule 13G, reporting a 0.5% beneficial ownership stake in Sarepta Therapeutics, Inc.
NASDAQ
D. E. Shaw & Co., L.P. and David E. Shaw have filed an amended Schedule 13G, disclosing a 5.1% beneficial ownership in Sarepta Therapeutics, Inc. and correcting a prior omission.
NASDAQ
D. E. Shaw & Co., L.P. and David E. Shaw have disclosed a beneficial ownership of 5.1% in Sarepta Therapeutics, Inc. common stock, signaling a significant passive investment.
NASDAQ
Capital International Investors has filed an amended Schedule 13G, revealing a beneficial ownership of 9.3% in Sarepta Therapeutics, Inc. as of December 31, 2024.